​

Inhibrx Biosciences (INBX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

INBX Stock Rating

Inhibrx Biosciences stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

INBX Price Target Upside V Benchmarks

TypeNameUpside
StockInhibrx Biosciences-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$74.66$74.66$74.66
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26--1--1
Dec, 25--1--1
Nov, 25--1--1
Oct, 25--1--1
Sep, 25--1--1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 17, 2025CitigroupMarket PerformMarket Performhold
Nov 19, 2025CitigroupMarket PerformMarket Performhold
Jul 23, 2024JMP SecuritiesOutperformMarket Performinitialise
Aug 23, 2023JMP SecuritiesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-50 $-10 $30 $70 $110 $150 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.15$-3.62$-5.12$114.01----
Avg Forecast$-2.16$-3.36$-4.39$-5.87$-6.17$-5.04$-2.43$-3.40
High Forecast$-2.16$-3.36$-4.29$-5.87$-6.17$-5.04$-2.43$-3.40
Low Forecast$-2.16$-3.36$-4.49$-5.87$-6.17$-5.04$-2.43$-3.40
Surprise %-0.46%7.74%16.63%-2042.25%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.13M$2.18M$1.80M$200.00K----
Avg Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
High Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Low Forecast$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Surprise %16.80%-16.23%620.00%-20.00%----

Net Income Forecast

$-500M $0 $500M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-81.77M$-145.23M$-241.36M$1.69B----
Avg Forecast$-84.59M$-97.33M$-271.15M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
High Forecast$-67.67M$-77.87M$-216.92M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Low Forecast$-101.50M$-116.80M$-325.39M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Surprise %-3.33%49.21%-10.99%-710.52%----

INBX Forecast FAQ

Is Inhibrx Biosciences stock a buy?

Inhibrx Biosciences stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inhibrx Biosciences is a favorable investment for most analysts.

What is Inhibrx Biosciences's price target?

Inhibrx Biosciences's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $74.66.

How does Inhibrx Biosciences stock forecast compare to its benchmarks?

Inhibrx Biosciences's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Inhibrx Biosciences over the past three months?

  • January 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Inhibrx Biosciences’s EPS forecast?

Inhibrx Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-6.17, marking a -105.41% decrease from the reported $114.01 in 2024. Estimates for the following years are $-5.04 in 2026, $-2.43 in 2027, and $-3.4 in 2028.

What is Inhibrx Biosciences’s revenue forecast?

Inhibrx Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $2M, reflecting a 897.50% increase from the reported $200K in 2024. The forecast for 2026 is $121.96M, followed by $337.85M for 2027, and $346.76M for 2028.

What is Inhibrx Biosciences’s net income forecast?

Inhibrx Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-291M, representing a -117.23% decrease from the reported $1.69B in 2024. Projections indicate $-238M in 2026, $-115M in 2027, and $-160M in 2028.